Muscle Relaxants (Cyclobenzaprine)

EBL lists no nutrient that this medication is shown to lower. The record exists so that what is listed below reaches anyone who enters this medication.

Magnesium. Magnesium is not a documented depletion caused by outpatient skeletal muscle relaxants (cyclobenzaprine, methocarbamol, baclofen, carisoprodol, tizanidine). Magnesium deficiency can itself produce cramps and neuromuscular symptoms, but randomized evidence for magnesium supplementation in idiopathic or nocturnal leg cramps is mixed and predominantly negative: Garrison et al. (Cochrane Database Syst Rev, 2020; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 32956536) found no clinically important benefit in older adults; Roguin Maor et al. (JAMA Intern Med, 2017; PMID 28241153) found magnesium oxide no better than placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received.; Kuusipalo et al. (Trials, 2026; PMID 41680812) found an adjusted mean difference of -0.20 cramps per week (95% CI -1.49 to 1.09, P=0.929) against placebo. Barna et al. (Nutr J, 2021; PMID 34719399) is the exception, reporting a modest improvement. Removed as a depletion row in August 2026.

Vitamin D3. Not a depletion caused by outpatient skeletal muscle relaxants. The cited association is Plotnikoff & Quigley (Mayo Clin Proc, 2003; PMID 14661675), a cross-sectional study of 150 primary-care patients with persistent nonspecific musculoskeletal pain; it measured no medication exposure and did not study cyclobenzaprine, methocarbamol, baclofen, carisoprodol or tizanidine. The association is also inconsistent: Warner & Arnspiger (J Clin Rheumatol, 2008; PMID 18431091) found diffuse musculoskeletal pain not associated with low vitamin D, and vitamin D no better than placebo in deficient participants. Schreuder et al. (Ann Fam Med, 2012; PMID 23149532) found a small benefit, in non-Western immigrants, treating deficiency rather than a drug effect. Robien et al. (Nutr Clin Pract, 2013; PMID 23307906), a systematic review A review that searches for every study on a question using a method set in advance, then assesses them together. of drug-vitamin D interactions, does not identify skeletal muscle relaxants as a depleting class. Removed as a depletion row in August 2026.

CoQ10. Not a depletion caused by outpatient skeletal muscle relaxants. No human or animal study has measured CoQ10 on cyclobenzaprine. The row rested on cyclobenzaprine's structural similarity to the tricyclics, documented in Hucker et al. (Drug Metab Dispos, 1978; PMID 33029), which establishes structure and disposition, not nutrient effect. The amitriptyline literature is indirect and does not transfer: Moreno-Fernandez et al. (J Psychiatr Res, 2012; PMID 22118833) is uncontrolled and confounded by depression itself; Bautista-Ferrufino et al. (Toxicol Lett, 2011; PMID 21501668) is a mouse study reporting deficiency in lung and liver; Cordero et al. (Toxicol Appl Pharmacol, 2009; PMID 19263520) is fibroblast and zebrafish; Ortiz et al. (Eur J Pharmacol, 2017; PMID 28099869) is a lung cancer cell line. Structural similarity to a different drug is not evidence about this one. Removed as a depletion row in August 2026.